Quinidine Inhibits In Vivo Metabolism of Amphetamine in Rats: Impact upon Correlation between GC/MS and Immunoassay Findings in Rat Urine*

David E. Moody, Werawan Ruangyuttikarn, Michael Y.L. Law

Journal of Analytical Toxicology · 1990 · 21 citations · 30 references

Concepts

Abstract

Amphetamine is metabolized by cytochrome P-450 (P450) to p-hydroxyamphetamine and phenylacetone in mammalian species. P450 metabolism is affected by genetic polymorphisms and by xenobiotic interactions in an isozyme-specific fashion. Little is known concerning the isozyme selectivity of amphetamine metabolism. Quinidine selectively inhibits the debrisoquine-specific isozyme (P450db) which displays genetic polymorphism in humans and rats. We now report the effect of quinidine on the metabolism of amphetamine to p-hydroxyamphetamine in vivo. At 0 h male Lewis rats received (po): no treatment (I), 80 mg quinidine/kg in 50% ethanol (II), or 50% ethanol (III), followed at 2 h by 15 mg d-amphetamine sulfate/kg (po). Urine specimens were collected and pooled at 0, 24, and 48 h. Amphetamine and p-hydroxyamphetamine concentrations were determined using a new GC/MS method for simultaneous quantitation. The ethanol vehicle-control (III) had no significant effect on amphetamine metabolism. Quinidine pretreatment (II) resulted in a significant decrease in the excretion of p-hydroxyamphetamine at 24 and 48 h to 7.2 and 24.1% of the vehicle-control levels, respectively, accompanied by a significant increase in amphetamine excretion between 24 and 48 h to 542% of the control. These data show that quinidine inhibits in vivo metabolism of amphetamine in rats and suggest that amphetamine metabolism may, in part, be mediated by an isozyme of P450 which displays genetic polymorphism. The inhibition of amphetamine metabolism results in an increased ratio of parent drug to metabolite concentration (metabolic ratio) in the urine, which mimics the effect of genetic polymorphisms. Because metabolites may contribute to the immunoreactive response in immunoassays, this alteration in metabolic ratio has the potential of affecting the results of immunoassays. Cross-reactivity studies have demonstrated that p-hydroxyamphetamine is recognized by commercial amphetamine immunoassays to a greater degree than the metabolites benzoic acid and phenylacetone. Using rat urine containing alterations in the metabolic ratio, we found that an increase in the ratio was associated with a decrease in the percentage of nonconfirmed immunoassay results. Genetic polymorphisms or drug interactions may therefore affect the number of samples identified as presumptive positives.

References

30